Quidel Q1 Revenues Drop 26 Percent | GenomeWeb

NEW YORK (GenomeWeb) — Quidel said after the close of the market Wednesday that first quarter revenues fell 26 percent to $46.7 million from $62.7 million in Q1 2013.

The decrease in revenue was due to lower sales of infectious disease products in Q1 2014, the result of a weak respiratory disease season.

In Q1, the company generated $18.3 million in total influenza product sales, as a year-over-year decrease in QuickVue Influenza product sales was partially offset by $6.2 million in Sofia Influenza revenue, a 42 percent increase over Q1 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."